ACM
CDLX icon

AlphaCrest Capital Management’s Cardlytics CDLX Stock Holding History

AlphaCrest Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,327
Closed -$595K – 200
2022
Q3 		$595K Buy
+6,327
New +$901K 0.04% 902
2021
Q2 		– Sell
-376
Closed -$413K – 1236
2021
Q1 		$413K Buy
+376
New +$496K 0.02% 890

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
GEH
General Equity Holdings Brooklyn, New York $135M AUM 32.96% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

AlphaCrest Capital Management's CDLX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Cardlytics (CDLX) in Q4 2022, closing a stake of 6,327 shares — an estimated $595K sold.

AlphaCrest Capital Management first reported a position in CDLX in Q1 2021 and held it in 2 quarters. The position peaked at $595K in Q3 2022. 121 funds tracked by Wall St. Rank hold CDLX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Cardlytics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 6,327 Cardlytics shares in Q4 2022, an estimated $595K.
  • AlphaCrest Capital Management first reported a position in Cardlytics in Q1 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's Cardlytics position peaked at $595K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Cardlytics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.